Danaher sees earnings lift from Masimo deal and bioprocessing rebound

According to CNBC, Danaher is expected to accelerate earnings as bioprocessing demand recovers and its recently closed $9.9 billion acquisition of Masimo begins to contribute. New CFO Matthew Gugino said on the first-quarter earnings call in April that the deal is expected to add roughly 15 to 20 cents to adjusted earnings per share in the first full year after closing, and Danaher is targeting $125 million in cost savings. The article also said Danaher expects to improve Masimo's margins through procurement, manufacturing and sales execution, while its core life sciences business is emerging from a two-year post-pandemic destocking period. It added that equipment orders have risen sequentially for three straight quarters, book-to-bill has normalized and management has guided for high single-digit growth in bioprocessing this year.